Altimmune, Inc.
ALT
$4.07
$0.071.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | 8.90% | -19.99% | |||
| Gross Profit | -8.91% | 19.99% | |||
| SG&A Expenses | -5.04% | 17.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.07% | -12.27% | |||
| Operating Income | -5.07% | 12.27% | |||
| Income Before Tax | -9.33% | 12.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.13% | 15.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.13% | 15.55% | |||
| EBIT | -5.07% | 12.27% | |||
| EBITDA | -5.08% | 12.27% | |||
| EPS Basic | -4.90% | 20.35% | |||
| Normalized Basic EPS | -1.37% | 17.56% | |||
| EPS Diluted | -4.90% | 20.35% | |||
| Normalized Diluted EPS | -1.37% | 17.56% | |||
| Average Basic Shares Outstanding | 7.85% | 6.02% | |||
| Average Diluted Shares Outstanding | 7.85% | 6.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||